Please assess the completion status of the following clinical trial:

Trial Title: REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute myocardial infarction (ST elevation in at least 2 leads \>= 0.2 mV in V1,V2 or V3 or \>= 0.1 mV in other leads), treated by one of the following procedures~  * Either acute PCI with stent implantation within 24 hours after symptom onset or~ * treatment with thrombolysis within 12 hours of symptom onset followed by PCI with stent implantation within 24 hours after thrombolysis.~* Acute PCI / stent implantation has been successful (residual stenosis visually \< 30% and TIMI flow \>= 2).~* At the time of inclusion patient does no longer require i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump)~* Significant regional wall motion abnormality in LV angiogram at the time of acute PCI (ejection fraction \<= 45% on visual estimation).~* Maximal CK elevation \>= 400 U/l (measured at 37° C) with significant MB fraction \> 6%~* Age 18 - 80 Years~* Written informed consent~Exclusion Criteria:~* Regional wall motion abnormality outside the area involved in the index acute myocardial infarction.~* Need to revascularize additional vessels, outside the infarct artery.~* Arteriovenous malformations or aneurysms~* Active infection (CRP \> 10 mg/dl) now, or fever or diarrhea within last 4 weeks.~* Chronic inflammatory disease~* HIV infection or active hepatitis~* Neoplastic disease without documented remission within the past 5 years.~* Cerebrovascular insult within 3 months~* Impaired renal function (creatinine \> 2 mg/dl) at the time of cell therapy~* Significant liver disease (GOT \> 2x upper limit) or spontaneous INR \> 1,5)~* Anemia (hemoglobin \< 8.5 mg/dl)~* Platelet count \< 100.000/µl~* Hypersplenism~* Known allergy or intolerance to clopidogrel, heparin or abciximab.~* History of bleeding disorder~* Gastrointestinal bleeding within 3 months~* Major surgical procedure or traumata within 2 months~* Uncontrolled hypertension~* Pregnancy~* Mental retardation~* Previously performed stem / progenitor cell therapy~* Participation in another clinical trial within the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BMC (Type: EXPERIMENTAL): Intracoronary infusion of autologous bone marrow derived cells
- Placebo (Type: PLACEBO_COMPARATOR): Intracoronary infusion of Placebo medium

Based on this trial design, predict the completion outcome and termination type (if applicable).